|Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as ...|
The Phase 3, randomized, double-blind, placebo-controlled STORM (Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma) trial is an international multicenter study that evaluated clinical benefit of sorafenib ...
Wall Street Journal - Tue, 11 Mar 2014 00:30
|Bayer And Onyx Say Nexavar Fails To Meet Primary Endpoint In Liver Cancer Trial|
RTT News - Tue, 11 Mar 2014 01:03
|Nexavar Does Not Meet Endpoint|
WKRB News - Tue, 11 Mar 2014 11:11
|Nexavar disappoints in Ph III liver cancer study|
The Pharma Letter - Tue, 11 Mar 2014 08:33
|Smoking Impacts Renal Cell Carcinoma Survival|
(HealthDay News) — For patients with clear cell renal cell carcinoma, smoking exposure adversely impacts cancer-specific survival and increases the risk of death from another cause, according to a study published in the March issue of The Journal of ...
Monthly Prescribing Reference - Thu, 27 Feb 2014 10:56
|Adverse Effect of Smoking on Survival Related To Cancer|
Health and Beauty News (blog) - Sat, 01 Mar 2014 08:52
|Aggressive secondary squamous carcinoma appeared during BRAF inhibitor ...|
A woman undergoing BRAF inhibitor targeted therapy for advanced melanoma has presented with invasive spindle cell squamous carcinoma masquerading as a secondary cutaneous squamous cell carcinoma, highlighting the importance of histologic ...
The Oncology Report - Wed, 26 Feb 2014 13:00
|Novartis investigational compound LDE225 met primary endpoint in pivotal trial ...|
(Thomson Reuters ONE via COMTEX) -- Novartis International AG / Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma . Processed and transmitted by NASDAQ OMX Corporate ...
MarketWatch - Tue, 18 Feb 2014 22:17
|Novartis: LDE225 Meets Primary Endpoint In Advanced Basal Cell Carcinoma Trial|
NASDAQ - Tue, 18 Feb 2014 22:56
|Novartis' LDE225 met primary endpoint in pivotal trial for advanced basal cell ...|
The Pharma Letter - Wed, 19 Feb 2014 08:22
|Novartis Cancer Drug Meets Primary Endpoint in Phase 2|
Drug Discovery & Development - Wed, 19 Feb 2014 07:11
|Novartis skin cancer drug meets endpoint in trial|
Medical Marketing and Media - Wed, 19 Feb 2014 12:15
|Novartis releases positive results of Phase II trial of BCC drug sonidegib|
Pharmaceutical Business Review - Wed, 19 Feb 2014 21:59
|Merkel cell carcinoma tumors posed risk for nodal involvement regardless of size|
Patients with small Merkel cell carcinoma tumors had a significant risk for nodal involvement, with less nodes predictive of longer survival, according to recent study results. Researchers analyzed 8,044 Merkel cell carcinoma (MCC) cases (61% men) in ...
Healio - Tue, 25 Feb 2014 09:03
|Some With Micropapillary Urothelial Carcinoma May Benefit From HER2 ...|
Some patients with micropapillary urothelial carcinoma face a three-fold risk of cancer death because their disease amplifies HER2 and overexpresses its protein product, and there may be a role for treatment of the condition with HER2- targeted agent ...
OncLive - Thu, 27 Feb 2014 07:00
|Common Antifungal Drug Works in Basal Cell Carcinoma|
The common antifungal drug itraconazole may be useful in treating basal cell carcinoma (BCC), according a phase 2 study published online February 3 in the Journal of Clinical Oncology. Itraconazole showed anti-BCC activity in a 29-patient study: 24% of ...
Medscape - Mon, 10 Feb 2014 15:54
|Research and Markets: Adrenocortical Carcinoma (Adrenal Cortex Cancer ...|
'Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex ...
Fort Mills Times - Tue, 18 Feb 2014 00:26